Because the inhibition of mTORC2 results in a paradoxical effect of experimental PH, we suggest that therapeutic regimens using inhibitors of the PI3K/AKT/mTOR signaling cascade for the treatment of PH and PAH should include an inhibitor of PDGFR (e.g., imatinib) due to the up-regulation of PDGFRα and PDGFRβ induced by mTORC2 inhibition.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: Idiopathic PAH is a fatal and progressive disease characterized by increased PVR creating strain on the right ventricle that can progress to right heart failure and death. Here, PDGFRA is linked to pulmonary arterial hypertension.